Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Couch

Showing results (381-390 of 697) with videos related to

Pageof 70
Sort By:
American Journal of Human Genetics|September 18, 2025
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variantsMarcy E Richardson, Megan F H Bishop, Megan A Holdren, et al.
Breast Cancer Research and Treatment|November 1, 2011
The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variantChristina Justenhoven, Ofure Obazee, Stefan Winter, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>Joanne Kotsopoulos, Adriana I Apostol, Kelly Metcalfe, et al.
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
NPJ Digital Medicine|June 15, 2026
Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier statusNicolas M Viart, Lucie Thibault, Tristan Lazard, et al.
NPJ Breast Cancer|February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patientsNadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Communications Biology|February 23, 2023
MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogrammingWazim Mohammed Ismail, Amelia Mazzone, Flavia G Ghiraldini, et al.
Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Pageof 70

Showing results (381-390 of 697) with videos related to

Sort By:
Pageof 70
American Journal of Human Genetics|September 18, 2025
Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline PALB2 sequence variantsMarcy E Richardson, Megan F H Bishop, Megan A Holdren, et al.
Breast Cancer Research and Treatment|November 1, 2011
The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variantChristina Justenhoven, Ofure Obazee, Stefan Winter, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>Joanne Kotsopoulos, Adriana I Apostol, Kelly Metcalfe, et al.
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
NPJ Digital Medicine|June 15, 2026
Deep learning analysis of breast cancer histology predicts ATM pathogenic variant carrier statusNicolas M Viart, Lucie Thibault, Tristan Lazard, et al.
NPJ Breast Cancer|February 13, 2020
Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patientsNadine Norton, Bahaaeldin Youssef, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.
Communications Biology|February 23, 2023
MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogrammingWazim Mohammed Ismail, Amelia Mazzone, Flavia G Ghiraldini, et al.
Journal of the National Cancer Institute|March 6, 2018
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation CarriersBritta Weigelt, Rui Bi, Rahul Kumar, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Pageof 70